HOCO-Leu-Leu-Leu-al

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: HOCO-Leu-Leu-Leu-al
• 英文别名: [(2S)-4-methyl-1-[[(2S)-4-methyl-1-[[(2S)-4-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]carbamic acid
• 化学式: C₁₉H₃₅N₃O₅
• 分子量: 385.5
• InChiKey: HMOSMMMCCKCXQE-JYJNAYRXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  27
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  125
• 氢给体数：
  4
• 氢受体数：
  5

文献信息

• Optimized CRISPR/cas9 systems and methods for gene editing in stem cells
  申请人：Editas Medicine, Inc.

  公开号：US11390884B2

  公开（公告）日：2022-07-19

  The methods and compositions described herein surprisingly increase CRISPR/Cas-mediated gene editing in stem cells by transiently treating the cells with a stem cell viability enhancer prior to and/or after contacting the cells with one or more CRISPR/Cas9 components. Further, this treatment also surprisingly results in increased engraftment of the stem cells into the target tissue of a subject. The present disclosure also provides one or more modified CRISPR/Cas9 components which, when used in combination with the stem cell viability enhancer, further increases the frequency of gene editing in stem cells, increases stem cell viability, and increases stem cell engraftment.

  本文所述的方法和组合物在干细胞与一种或多种CRISPR/Cas9成分接触之前和/或之后，用干细胞活力增强剂瞬时处理细胞，从而令人惊讶地增加了干细胞中CRISPR/Cas介导的基因编辑。此外，这种处理方法还令人惊奇地增加了干细胞在受试者靶组织中的移植。本公开还提供了一种或多种经修饰的CRISPR/Cas9成分，当与干细胞活力增强剂结合使用时，可进一步增加干细胞基因编辑的频率，提高干细胞活力，增加干细胞移植。
• METHODS FOR IN VITRO INVESTIGATING MITOCHONDRIAL REPLICATION DYSFUNCTION IN A BIOLOGICAL SAMPLE, KITS AND USES THEREOF, THERAPEUTIC METHODS AGAINST PROGEROID-LIKE SYNDROMES OR SYMPTOMES AND SCREENING METHOD FOR IDENTIFYING PARTICULAR PROTEASE INHIBITOR(S) AND/OR NITROSO-REDOX STRESS SCAVENGER COMPOUND(S)
  申请人：Institut Pasteur

  公开号：EP3105596A1

  公开（公告）日：2016-12-21
• OPTIMIZED CRISPR/CAS9 SYSTEMS AND METHODS FOR GENE EDITING IN STEM CELLS
  申请人：Editas Medicine, Inc.

  公开号：EP3294896A1

  公开（公告）日：2018-03-21
• METHODS FOR INDUCTION OF CELL FATES FROM PLURIPOTENT CELLS
  申请人：THE CLEVELAND CLINIC FOUNDATION

  公开号：US20150368616A1

  公开（公告）日：2015-12-24

  A method of inducing pancreatic fates from human multipotent or pluripotent cells includes obtaining a cell population comprising human multipotent or pluripotent cells and providing the cell population with at least three of (i) an CXCR4 agonist, (ii) an EGFR agonist, (iii) an FGFR agonist, (iv) an Activin receptor agonist or an agent that stimulates SMAD3, (v) an IL11R agonist or IL6R agonist, (vi) a notch agonist, (vii) an RXR agonist or RAR agonist, or (viii) a BMP inhibitor for a time effective to allow the differentiation of pancreatic precursor cells from the human multipotent or pluripotent cells.
• COMBINATION THERAPIES
  申请人：INFINITY PHARMACEUTICALS, INC.

  公开号：US20170348314A1

  公开（公告）日：2017-12-07

  Provided herein are pharmaceutical compositions comprising a phosphatidylinositol 3-kinase inhibitor, or pharmaceutically acceptable form thereof, in combination with a second agent, or a pharmaceutically acceptable form thereof, wherein the second agent is chosen from one or more of 1) a CDK4/6 inhibitor, 2) an HDAC inhibitor, 3) a MEK inhibitor, 4) a mTOR inhibitor, 5) an AKT inhibitor, 6) a proteasome inhibitor, 7) an immunomodulator, 8) a glucocorticosteroid, 9) a BET inhibitor, 10) an epigenetic inhibitor, 11) a PI3K alpha inhibitor, 12) a topoisomerase inhibitor, or 13) an ERK inhibitor. Also provided herein are methods of treatment comprising administration of the compositions, and uses of the compositions, e.g., for treatment of cancer.